Extracellular Vesicles Produced by the Probiotic Propionibacterium freudenreichii CIRM-BIA 129 Mitigate Inflammation

Vinícius de Rezende Rodovalho1,2, Brenda Silva Rosa da Luz1,2, Houem Rabah1

  • 1INRAE, Institut Agro, STLO, Rennes, France.

Insights

Propionibacterium freudenreichii bacteria release extracellular vesicles (EVs) carrying immunomodulatory proteins like SlpB. These bacterial EVs reduce inflammation in human cells by modulating the NF-κB pathway, offering therapeutic potential.

Area of Science:

  • Microbiology and Immunology
  • Cell Biology
  • Bacterial Physiology

Background:

  • Extracellular vesicles (EVs) mediate intercellular communication and are involved in bacterial processes like pathogenesis and immunomodulation.
  • Certain probiotic Propionibacterium freudenreichii strains possess anti-inflammatory properties, partly attributed to surface proteins like SlpB.
  • The potential role of EVs in exporting immunomodulatory proteins by P. freudenreichii remains unexplored.

Purpose of the Study:

  • To investigate the production and characterization of EVs from the probiotic P. freudenreichii strain CIRM-BIA 129.
  • To identify proteins within these EVs, focusing on immunomodulatory molecules.
  • To assess the functional impact of these bacterial EVs on host inflammatory responses.

Main Methods:

  • Purification of EVs from P. freudenreichii culture supernatants.
  • Physicochemical characterization using transmission electron microscopy and nanoparticle tracking analysis (NTA).
  • Proteomic analysis of EV content and in silico prediction of protein-protein interactions.
  • Functional assays in HT-29 cells measuring IL-8 release and NF-κB activity.

Main Results:

  • P. freudenreichii CIRM-BIA 129 produced EVs with typical morphology and size.
  • EVs contained diverse proteins, including the immunomodulatory SlpB, and were predicted to interact with host proteins like NF-κB.
  • Bacterial EVs demonstrated anti-inflammatory effects by modulating NF-κB activity and IL-8 release in HT-29 cells, dependent on EV concentration and inducer.

Conclusions:

  • This study provides the first identification and characterization of EVs derived from P. freudenreichii.
  • Bacterial EVs contribute to the probiotic effects of P. freudenreichii by modulating host inflammatory pathways.
  • P. freudenreichii-derived EVs represent a promising avenue for developing novel bioactive products for therapeutic applications.

Related Concept Videos

Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
15.5K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
9.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
351
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
341